Equities researchers at Jefferies Group LLC began coverage on shares of Epizyme, Inc. (NASDAQ:EPZM) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating and a $23.00 price target on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective would indicate a potential upside of 22.99% from the company’s current price.

A number of other research analysts have also recently commented on the company. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research report on Tuesday. Cann restated a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research report on Tuesday. Royal Bank Of Canada restated a “buy” rating and issued a $20.00 price target on shares of Epizyme in a research report on Friday, September 15th. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Finally, Leerink Swann restated an “outperform” rating and issued a $28.00 price target (down previously from $31.00) on shares of Epizyme in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $23.33.

Epizyme (EPZM) opened at 18.70 on Wednesday. Epizyme has a 12 month low of $8.38 and a 12 month high of $19.60. The company’s market cap is $1.09 billion. The company’s 50-day moving average is $15.50 and its 200-day moving average is $15.25.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.95 million. During the same quarter last year, the firm earned ($0.49) earnings per share. The company’s revenue was up 2027.7% on a year-over-year basis. On average, equities research analysts anticipate that Epizyme will post ($2.36) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/21/jefferies-group-llc-initiates-coverage-on-epizyme-inc-epzm.html.

In other Epizyme news, Director David M. Mott bought 200,000 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were purchased at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now directly owns 6,000 shares in the company, valued at approximately $91,500. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $15.68, for a total value of $235,200.00. Following the completion of the transaction, the insider now owns 22,228 shares in the company, valued at approximately $348,535.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,024 shares of company stock worth $706,722. Company insiders own 25.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in Epizyme by 61.4% in the first quarter. Dimensional Fund Advisors LP now owns 65,194 shares of the biopharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 24,807 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Epizyme by 25.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 161,646 shares of the biopharmaceutical company’s stock valued at $2,773,000 after acquiring an additional 32,650 shares during the last quarter. Palo Alto Investors LLC grew its position in Epizyme by 57.8% in the first quarter. Palo Alto Investors LLC now owns 4,791,051 shares of the biopharmaceutical company’s stock valued at $82,167,000 after acquiring an additional 1,755,255 shares during the last quarter. American International Group Inc. grew its position in Epizyme by 7.1% in the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock valued at $425,000 after acquiring an additional 1,638 shares during the last quarter. Finally, Woodstock Corp grew its position in Epizyme by 5.5% in the second quarter. Woodstock Corp now owns 37,078 shares of the biopharmaceutical company’s stock valued at $560,000 after acquiring an additional 1,945 shares during the last quarter. Hedge funds and other institutional investors own 83.74% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.